232 related articles for article (PubMed ID: 19531451)
1. Guidelines for HER2 testing in breast cancer: a national consensus of the Spanish Society of Pathology (SEAP) and the Spanish Society of Medical Oncology (SEOM).
Albanell J; Andreu X; Calasanz MJ; Concha A; Corominas JM; García-Caballero T; López JA; López-Ríos F; Ramón y Cajal S; Vera-Sempere FJ; Colomer R; Martín M; Alba E; González-Martín A; Llombart A; Lluch A; Palacios J
Clin Transl Oncol; 2009 Jun; 11(6):363-75. PubMed ID: 19531451
[TBL] [Abstract][Full Text] [Related]
2. Consensus of the Spanish Society of Medical Oncology (SEOM) and Spanish Society of Pathology (SEAP) for HER2 testing in gastric carcinoma.
Gómez-Martín C; Concha A; Corominas JM; García-Caballero T; García-García E; Iglesias M; López JA; Ramón y Cajal S; Rojo F; Palacios J; Vera-Sempere F; Aranda E; Colomer R; García-Alfonso P; Garrido P; Rivera F; López-Ríos F; ;
Clin Transl Oncol; 2011 Sep; 13(9):636-51. PubMed ID: 21865135
[TBL] [Abstract][Full Text] [Related]
3. Updated UK Recommendations for HER2 assessment in breast cancer.
Rakha EA; Pinder SE; Bartlett JM; Ibrahim M; Starczynski J; Carder PJ; Provenzano E; Hanby A; Hales S; Lee AH; Ellis IO;
J Clin Pathol; 2015 Feb; 68(2):93-9. PubMed ID: 25488926
[TBL] [Abstract][Full Text] [Related]
4. Chromogenic in situ hybridisation (CISH) should be an accepted method in the routine diagnostic evaluation of HER2 status in breast cancer.
Di Palma S; Collins N; Faulkes C; Ping B; Ferns G; Haagsma B; Layer G; Kissin MW; Cook MG
J Clin Pathol; 2007 Sep; 60(9):1067-8. PubMed ID: 17293390
[No Abstract] [Full Text] [Related]
5. Prospective multi-centre study to validate chromogenic in situ hybridisation for the assessment of HER2 gene amplification in specimens from adjuvant and metastatic breast cancer patients.
Riethdorf S; Hoegel B; John B; Ott G; Fritz P; Thon S; Loening T; Pantel K
J Cancer Res Clin Oncol; 2011 Feb; 137(2):261-9. PubMed ID: 20396915
[TBL] [Abstract][Full Text] [Related]
6. Metastatic breast cancer of HER2 scored 2+ by IHC and HER2 gene amplification assayed by FISH has a good response to single agent therapy with trastuzumab: a case report.
Takahashi M; Inoue K; Goto R; Tamura M; Taguchi K; Takahashi H; Suzuki H; Katsushige K; Ogita M
Breast Cancer; 2003; 10(2):170-4. PubMed ID: 12736573
[TBL] [Abstract][Full Text] [Related]
7. HER2 testing recommendations in Australia.
Bilous M;
Pathology; 2001 Nov; 33(4):425-7. PubMed ID: 11827407
[TBL] [Abstract][Full Text] [Related]
8. HER2 testing in breast cancer: NCCN Task Force report and recommendations.
Carlson RW; Moench SJ; Hammond ME; Perez EA; Burstein HJ; Allred DC; Vogel CL; Goldstein LJ; Somlo G; Gradishar WJ; Hudis CA; Jahanzeb M; Stark A; Wolff AC; Press MF; Winer EP; Paik S; Ljung BM;
J Natl Compr Canc Netw; 2006 Jul; 4 Suppl 3():S1-22; quiz S23-4. PubMed ID: 16813731
[TBL] [Abstract][Full Text] [Related]
9. [HER2 testing for breast cancer. Swedish laboratories can now offer a quality assured analysis of growth factor].
Haglund M; Chebil G; Johansson L
Lakartidningen; 2005 Mar 7-13; 102(10):740-3. PubMed ID: 15839164
[TBL] [Abstract][Full Text] [Related]
10. HER2 status in breast cancer: experience of a Spanish National Reference Centre.
Cuadros M; Cano C; López FJ; Talavera P; García-Peréz I; Blanco A; Concha Á
Clin Transl Oncol; 2011 May; 13(5):335-40. PubMed ID: 21596662
[TBL] [Abstract][Full Text] [Related]
11. HER2 testing in breast carcinoma: very low concordance rate between reference and local laboratories in Brazil.
Wludarski SC; Lopes LF; Berto E Silva TR; Carvalho FM; Weiss LM; Bacchi CE
Appl Immunohistochem Mol Morphol; 2011 Mar; 19(2):112-8. PubMed ID: 20930616
[TBL] [Abstract][Full Text] [Related]
12. Standardization of HER2 testing: results of an international proficiency-testing ring study.
Dowsett M; Hanna WM; Kockx M; Penault-Llorca F; Rüschoff J; Gutjahr T; Habben K; van de Vijver MJ
Mod Pathol; 2007 May; 20(5):584-91. PubMed ID: 17396141
[TBL] [Abstract][Full Text] [Related]
13. HER2 testing in the UK: further update to recommendations.
Walker RA; Bartlett JM; Dowsett M; Ellis IO; Hanby AM; Jasani B; Miller K; Pinder SE
J Clin Pathol; 2008 Jul; 61(7):818-24. PubMed ID: 18381380
[TBL] [Abstract][Full Text] [Related]
14. HER2 testing in the UK: recommendations for breast and gastric in-situ hybridisation methods.
Bartlett JM; Starczynski J; Atkey N; Kay E; O'Grady A; Gandy M; Ibrahim M; Jasani B; Ellis IO; Pinder SE; Walker RA
J Clin Pathol; 2011 Aug; 64(8):649-53. PubMed ID: 21690244
[TBL] [Abstract][Full Text] [Related]
15. Clinicopathologic characteristics of HER2 FISH-ambiguous breast cancer at a single institution.
Clay MR; Iberri DJ; Bangs CD; Cherry A; Jensen KC
Am J Surg Pathol; 2013 Jan; 37(1):120-7. PubMed ID: 23108020
[TBL] [Abstract][Full Text] [Related]
16. HER2 status in breast cancer--an example of pharmacogenetic testing.
Kroese M; Zimmern RL; Pinder SE
J R Soc Med; 2007 Jul; 100(7):326-9. PubMed ID: 17606754
[TBL] [Abstract][Full Text] [Related]
17. HER2+ breast cancer: review of biologic relevance and optimal use of diagnostic tools.
Hicks DG; Kulkarni S
Am J Clin Pathol; 2008 Feb; 129(2):263-73. PubMed ID: 18208807
[TBL] [Abstract][Full Text] [Related]
18. [Diagnosis of HER2 gene amplification in breast carcinoma].
Couturier J; Vincent-Salomon A; Mathieu MC; Valent A; Bernheim A
Pathol Biol (Paris); 2008 Sep; 56(6):375-9. PubMed ID: 18456424
[TBL] [Abstract][Full Text] [Related]
19. HER2 (erbB-2)-targeted effects of the omega-3 polyunsaturated fatty acid, alpha-linolenic acid (ALA; 18:3n-3), in breast cancer cells: the "fat features" of the "Mediterranean diet" as an "anti-HER2 cocktail".
Menéndez JA; Vázquez-Martín A; Ropero S; Colomer R; Lupu R
Clin Transl Oncol; 2006 Nov; 8(11):812-20. PubMed ID: 17134970
[TBL] [Abstract][Full Text] [Related]
20. Discrepancies in clinical laboratory testing of eligibility for trastuzumab therapy: apparent immunohistochemical false-positives do not get the message.
Tubbs RR; Pettay JD; Roche PC; Stoler MH; Jenkins RB; Grogan TM
J Clin Oncol; 2001 May; 19(10):2714-21. PubMed ID: 11352964
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
